title: LCZ696: the next step in improving RAS inhibition?
abstract: LCZ696 is a single molecule which combines the angiotensin receptor blocker valsartan with the neprilysn inhibitor sacubitril (AHU377). In the recently published PARADIGM-HF trial, LCZ696 proved superior to enalapril in reducing overall mortality, heart failure hospitalizations, and other endpoints in patients with systolic dysfunction heart failure. Increases in counter-regulatory natriuretic peptides which oppose sodium retention, vasoconstriction, and the deleterious structural changes which follow neurohormonal activation are thought to account for these improved outcomes. In two large hypertension studies, LCZ696 has proved to be a potent, effective antihypertensive agent with tolerability similar to valsartan and placebo and potency comparable to amlodipine. Although several have occurred in the heart failure population, there have been no cases of angioedema noted in the hypertension trials, although few black patients-a group at high risk for its occurrence-have been studied. Whether LCZ696 will displace angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (ARBs) as preferred renin-angiotensin system (RAS) blocking agents in hypertension will require demonstration of improved long-term outcomes compared with currently preferred first-line drugs. In this regard, experience has shown that it is difficult to extrapolate results achieved in heart failure to the treatment of hypertension, a condition in which neurohormonal activation is less critical in determining long-term prognosis. It will be particularly important to demonstrate renal protection with LCZ696 in patients with diabetes, proteinuria, and hypertension-the only therapeutic area other than heart failure in which RAS blockade has proved essential for optimal endpoint reduction. Superiority over available RAS blockers in terms of 'vascular protection' in high-risk populations represents another path to acceptance of LCZ696 as a preferred agent in cardiovascular medicine.
authors.affiliation: Temple University School of Medicine (Clinical Campus), 1239 Shady Avenue, Pittsburgh, PA, 15232, USA, gradmanmd@aol.com.
authors.forename: Alan H
authors.initials: AH
authors.lastname: Gradman
mesh_terms: D000613:Aminobutyrates / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D001713:Biphenyl Compounds; D004338:Drug Combinations; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D012084:Renin-Angiotensin System / Q000187:drug effects; D013777:Tetrazoles / Q000627:therapeutic use*; D000068756:Valsartan; D018631:ras Proteins / Q000037:antagonists & inhibitors*
chemical_list: D000613:Aminobutyrates; D000806:Angiotensin-Converting Enzyme Inhibitors; D001713:Biphenyl Compounds; D004338:Drug Combinations; D013777:Tetrazoles; D000068756:Valsartan; D018631:ras Proteins; C549068:sacubitril and valsartan sodium hydrate drug combination
references.citation: Hypertension. 1995 Dec;26(6 Pt 2):1160-6
references.pmid: 7498988
references.citation: N Engl J Med. 2014 Apr 10;370(15):1383-92
references.pmid: 24716680
references.citation: Lancet. 2012 Oct 20;380(9851):1387-95
references.pmid: 22932717
references.citation: N Engl J Med. 1991 Aug 1;325(5):293-302
references.pmid: 2057034
references.citation: Circulation. 2002 Aug 20;106(8):920-6
references.pmid: 12186794
references.citation: Lancet. 2003 Sep 6;362(9386):767-71
references.pmid: 13678869
references.citation: JAMA. 2002 Dec 18;288(23):2981-97
references.pmid: 12479763
references.citation: Hypertension. 2001 Dec 1;38(6):1342-8
references.pmid: 11751715
references.citation: Kidney Int. 2001 Aug;60(2):715-21
references.pmid: 11473654
references.citation: J Clin Pharmacol. 2010 Apr;50(4):401-14
references.pmid: 19934029
references.citation: J Am Soc Nephrol. 2001 Oct;12(10):2051-9
references.pmid: 11562403
references.citation: J Hypertens. 1992 Jul;10(7):607-13
references.pmid: 1321186
references.citation: N Engl J Med. 1992 Sep 3;327(10):669-77
references.pmid: 1386652
references.citation: N Engl J Med. 2001 Sep 20;345(12):851-60
references.pmid: 11565517
references.citation: N Engl J Med. 1999 Sep 2;341(10):709-17
references.pmid: 10471456
references.citation: Lancet. 2010 Apr 10;375(9722):1255-66
references.pmid: 20236700
references.citation: Eur Heart J. 2006 Oct;27(19):2338-45
references.pmid: 16963472
references.citation: N Engl J Med. 2001 Dec 6;345(23):1667-75
references.pmid: 11759645
references.citation: Lancet. 2004 Jun 19;363(9426):2022-31
references.pmid: 15207952
references.citation: N Engl J Med. 2001 Sep 20;345(12):861-9
references.pmid: 11565518
references.citation: JACC Heart Fail. 2014 Dec;2(6):663-70
references.pmid: 25306450
references.citation: Hypertension. 2014 Apr;63(4):698-705
references.pmid: 24446062
references.citation: N Engl J Med. 2011 Jan 6;364(1):11-21
references.pmid: 21073363
references.citation: Eur Heart J. 2013 Mar;34(12):886-893c
references.pmid: 22942338
references.citation: N Engl J Med. 1993 Nov 11;329(20):1456-62
references.pmid: 8413456
references.citation: N Engl J Med. 2001 May 31;344(22):1651-8
references.pmid: 11386263
references.citation: J Cardiovasc Pharmacol. 1999 Dec;34(6):782-90
references.pmid: 10598120
references.citation: N Engl J Med. 2014 Sep 11;371(11):993-1004
references.pmid: 25176015
references.citation: N Engl J Med. 2004 Nov 11;351(20):2058-68
references.pmid: 15531767
references.citation: N Engl J Med. 2008 Apr 10;358(15):1547-59
references.pmid: 18378520
references.citation: N Engl J Med. 2000 Jan 20;342(3):145-53
references.pmid: 10639539
references.citation: N Engl J Med. 2008 Dec 4;359(23):2456-67
references.pmid: 19001508
references.citation: JACC Heart Fail. 2013 Aug;1(4):308-314
references.pmid: 24621933
references.citation: Lancet. 2008 Sep 27;372(9644):1174-83
references.pmid: 18757085
references.citation: Lancet. 2003 Sep 6;362(9386):777-81
references.pmid: 13678871
references.citation: Lancet. 1999 Jan 2;353(9146):9-13
references.pmid: 10023943
references.citation: JAMA. 2000 Mar 8;283(10):1295-302
references.pmid: 10714728
references.citation: N Engl J Med. 2012 Dec 6;367(23):2204-13
references.pmid: 23121378
references.citation: Am J Hypertens. 2004 Feb;17(2):103-11
references.pmid: 14751650
references.citation: Expert Opin Investig Drugs. 1999 Jan;8(1):79-84
references.pmid: 15992061
references.citation: N Engl J Med. 2011 Jul 7;365(1):32-43
references.pmid: 21732835